Clinical Trials Update provides you with latest news about clinical trials conducted by MVA member companies. The update gives insight to progress in studies, results and possible indications. 

NatImmune Initiates Phase IIb Clinical Study with BAMLET in Denmark

21 April - NatImmune have announced the initiation of a phase IIb clinical trial designed to evaluate the safety and efficacy of its BAMLET Topical Gel, a protein-lipid based proprietary dermatological product candidate, for the treatment of recalcitrant warts in immuno-suppressed kidney-transplanted patient when applied locally to wart lesions.

Results from the phase IIb clinical trail are expected in the second half of 2008 and these results, if positive, will form the basis for a decision to initiate phase III pivotal trial both in the USA and Europe in 2009.

The phase IIb clinical trial, which will be conducted at several dermatology centers and clinics in Denmark, will enroll approximately 120 patients in the double-blinded, placebo-controlled trial investigating two concentrations of BAMLET.

Read more